Systematic Review of Hormonal Contraception and Risk of Venous Thrombosis

Abstract

Background:

Hormonal contraception (HC) is widely used throughout the world and has been associated with venous thrombosis (VT) such as deep vein thrombosis, pulmonary emboli, and cerebral VT.

Objectives:

To provide a current comprehensive overview of the risk of objectively confirmed VT with HC in healthy women compared to nonusers.

Search methods:

PubMed was searched from inception to April 2018 for eligible studies in the English language, with hand searching from past systematic reviews.

Selection criteria:

We selected original research evaluating risk of objectively confirmed VT in healthy women taking oral or nonoral HC compared with nonusers.

Data collection:

The primary outcome of interest was a fatal or nonfatal VT in users of HC compared to nonusers or past users. Studies with at least twenty events were eligible. Adjusted relative risks with 95 percent confidence intervals were reported. Three independent reviewers extracted data from selected studies.

Results:

1,962 publications were retrieved through the search strategy, with 15 publications included. Users of oral contraception with levonorgesterol had increased risk of VT by a range of 2.79–4.07, while other oral hormonal preparations increased risk by 4.0–48.6. Levonorgestrel intrauterine devices did not increase risk. Etonogestrel/ethinyl estradiol vaginal rings increased the risk of VT by 6.5. Norelgestromin/ethinyl estradiol patches increased risk of VT by 7.9. Etonogestrel subcutaneous implants by 1.4 and depot-medroxyprogesterone by 3.6. The risk of fatal VT was increased in women aged fifteen to twenty-four by 18.8-fold.

Conclusion:

Users of HC have a significant increased risk of VT compared to nonusers. Current risks would project at least 300–400 healthy young women dying yearly in the United States due to HC. Women should be informed of these risks and offered education in fertility-awareness-based methods with comparable efficacy for family planning.

Summary:

HC is widely used throughout the world and has been associated with blood clots in the legs and lungs. We searched the literature and found the risks of currently used forms of birth control increased between three- and ninefold for blood clots for healthy women. The risks found would project 300–400 women dying from using HC each year in the United States.

Keywords

Hormonal contraception Oral contraception Pulmonary emboli Systematic review Venous thrombosis

Get full access to this article

View all access options for this article.

References

Andersen

B. S.

Olsen

Nielsen

G. L.

Steffensen

F. H.

Sorensen

H. T.

Baech

Gergersen

. 1998. “Third Generation Oral Contraceptives and Heritable Thrombophilia as Risk Factors of Non-fatal Venous Thromboembolism.” Thrombosis and Haemostasis 79:28–31.

Anderson

F. A.

Jr. Wheeler

H. B.

Goldberg

R. J.

Hosmer

D. W.

Patwardhan

N. A.

Jovanovic

Forcier

Dalen

J. E.

. 1991. “A Population-based Perspective of the Hospital Incidence and Case-fatality Rates of Deep Vein Thrombosis and Pulmonary Embolism: The Worcester Dvt Study.” Archives of Internal Medicine 151, no. 5: 933–38. doi: 10.1001/archinte.1991.00400050081016.

Bloemenkamp

K. W.

Rosendaal

F. R.

Helmerhorst

F. M.

Buller

H. R.

Vandenbroucke

J. P.

. 1995. “Enhancement by Factor V Leiden Mutation of Risk of Deep-vein Thrombosis Associated with Oral Contraceptives Containing a Third-generation Progestagen.” Lancet 346, no. 8990: 1593–96.

Bloemenkamp

K. W.

Rosendall

F. R.

Buller

H. R.

Helmerhorst

F. M.

Colly

L. P.

Vandenbrouke

J. P.

. 1999. “Risk of Venous Thrombosis with Use of Current Low Dose Oral Contraceptives Is Not Explained by Diagnostic Suspicioun and Referral Bias.” Archives of Internal Medicine 159: 65–70.

Daniels

2015, November 10. “Current Contraceptive Use and Variation by Selected Characteristics Among Women Aged 15–44: United States, 2011–2013.” National Health Statistics Reports 86: 1–15.

de Bastos

Stegeman

B. H.

Rosendaal

F. R.

Van Hylckama Vlieg

Helmerhorst

F. M.

Stijnen

Dekkers

O. M.

. 2014. “Combined Oral Contraceptives: Venous Thrombosis.” Cochrane Database of Systematic Reviews, no. 3: CD010813. doi: 10.1002/14651858.CD010813.pub2.

Golder

Loke

Yoon K.

Bland

Martin

. 2011. “Meta-analyses of Adverse Effects Data Derived from Randomised Controlled Trials as Compared to Observational Studies: Methodological Overview.” PLoS Medicine 8, no. 5: e1001026. doi: 10.1371/journal.pmed.1001026.

Gourbil

Grandvuillemin

Beyens

M. N.

Massy

Gras

D’Amico

Miremont-Salame

Petitpain

. 2014. “Thromboembolic Events in Women Exposed to Hormonal Contraception or Cyproterone Acetate in 2012: A Cross-sectional Observational Study in 30 French Public Hospitals.” Drug Safety 37, no. 4: 269–82. doi: 10.1007/s40264-014-0149-8.

Lewis

M. A.

1996. “The Increased Risk of Venous Thromboembolism and the Use of Third Generation Progestagens: Role of Bias in Observational Research.” Contraception 54:5–13.

10.

Lidegaard

Edstrom

Kreiner

. 2002. “Oral Contraceptives and Venous Thromboembolism: A Five-year National Case-control Study.” Contraception 65, no. 3: 187–96.

11.

Lidegaard

Øjvind

Løkkegaard

Ellen

Jensen

Aksel

Skovlund

Charlotte Wessel

Keiding

Niels

. 2012. “Thrombotic Stroke and Myocardial Infarction with Hormonal Contraception.” New England Journal of Medicine 366, no. 24: 2257–66. doi: 10.1056/NEJMoa1111840.

12.

Lidegaard

Nielsen

L. H.

Skovlund

C. W.

Lokkegaard

. 2012. “Venous Thrombosis in Users of Non-oral Hormonal Contraception: Follow-up Study, Denmark 2001–10.” British Medical Journal 344:e2990. doi: 10.1136/bmj.e2990.

13.

Lidegaard

Nielsen

L. H.

Skovlund

C. W.

Skjeldestad

F. E.

Lokkegaard

. 2011. “Risk of Venous Thromboembolism from Use of Oral Contraceptives Containing Different Progestogens and Oestrogen Doses: Danish Cohort Study, 2001–9.” British Medical Journal 343:d6423. doi: 10.1136/bmj.d6423.

14.

Manhart

Michael D.

Duane

Marguerite

Lind

April

Sinai

Irit

Golden-Tevald

Jean

. 2013. “Fertility Awareness-based Methods of Family Planning: A Review of Effectiveness for Avoiding Pregnancy Using SORT.” Osteopathic Family Physician 5, no. 1: 2–8.

15.

Manzoli

2012. “Oral Contraceptives and Venous Thromboembolism a Systematic Review and Meta-analysis.” Drug Safety 35, no. 3: 191–205.

16.

Martinelli

1999. “Interaction between the G20210A Mutation of the Prothrombin Gene and Oral Contraceptive Use in Deep Vein Thrombosis.” Arteriosclerosis, Thrombosis, and Vascular Biology 19: 700–703.

17.

Martinelli

Maino

Abbattista

Bucciarelli

Passamonti

S. M.

Artoni

Gianniello

Peyvandi

. 2016. “Duration of Oral Contraceptive Use and the Risk of Venous Thromboembolism. A Case-control Study.” Thrombosis Research 141:153–57. doi: 10.1016/j.thromres.2016.03.025.

18.

Parkin

Skegg

D. C.

Wilson

Herbison

G. P.

Paul

. 2000. “Oral Contraceptives and Fatal Pulmonary Embolism.” Lancet 355, no. 9221: 2133–34. doi: 10.1016/s0140-6736(00)02382-5.

19.

Rossouw

J. E.

Anderson

G. L.

Prentice

R. L.

LaCroix

A. Z.

Kooperberg

Stefanick

M. L.

Jackson

R. D.

Beresford

S. A.

Howard

B. V.

Johnson

K. C.

Kotchen

J. M.

Ockene

. 2002. “Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results from the Women’s Health Initiative Randomized Controlled Trial.” Journal of the American Medical Association 288, no. 3: 321–33.

20.

Samuelsson

Hedenmalm

Persson

. 2005. “Mortality from Venous Thromboembolism in Young Swedish Women and Its Relation to Pregnancy and Use of Oral Contraceptives—An Approach to Specifying Rates.” European Journal of Epidemiology 20, no. 6: 509–16.

21.

Sidney

Petitti

D. B.

Soff

G. A.

Cundiff

D. L.

Tolan

K. K.

Quesenberry

C. P.

, Jr. 2004. “Venous Thromboembolic Disease in Users of Low-estrogen Combined Estrogen-progestin Oral Contraceptives.” Contraception 70, no. 1: 3–10. doi: 10.1016/j.contraception.2004.02.010.

22.

Suissa

Blais

Spitzer

W. O.

Cusson

Lewis

Heinemann

. 1997. “First-time Use of Newer Oral Contraceptives and the Risk of Venous Thromboembolism.” Contraception 56, no. 3: 141–46.

23.

van Hylckama Vlieg

Helmerhorst

F. M.

Rosendaal

F. R.

. 2010. “The Risk of Deep Venous Thrombosis Associated with Injectable Depot-medroxyprogesterone Acetate Contraceptives or a Levonorgestrel Intrauterine Device.” Arteriosclerosis, Thrombosis, and Vascular Biology 30, no. 11: 2297–300. doi: 10.1161/atvbaha.110.211482.

24.

van Hylckama Vlieg

Helmerhorst

F. M.

Vandenbroucke

J. P.

Doggen

C. J.

Rosendaal

F. R.

. 2009. “The Venous Thrombotic Risk of Oral Contraceptives, Effects of Oestrogen Dose and Progestogen Type: Results of the MEGA Case-control Study.” British Medical Journal 339:b2921. doi: 10.1136/bmj.b2921.

25.

WHO (World Health Organization). 1995a. “Effect of Different Progestagens in Low Oestrogen Oral Contraceptives on Venous Thromboembolic Disease.” Lancet 346:1582–88.

26.

WHO (World Health Organization). 1995b. “World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous Thromboembolic Disease and Combined Oral Contraception; Results of International Multicentre Case-control Study.” Lancet 346:1575–82.

27.

WHO (World Health Organization). 1998. “Cardiovascular Disease and Steroid Hormone Contraception. Report of a WHO Scientific Group.” World Health Organization Technical Report Series 877: i–vii, 1–89.